Arcturus Therapeutics Holdings Inc. $ARCT is set to be EBITDA positive in 2022 with a massive change in its revenue from 24.05M in 2021 to 326.44M in 2022. This is 12.57x increase in revenue. These numbers are estimates, but even with a large error margin we should see a drastic change in the price. Moreover, the decline from ATH was 80% and the price has been in a sideways movement after it bottomed. With today's strong breakout of the descending channel, I am expecting the price to start its rise up to the upper band of the range-bound around $63. The long-term targets should be a lot higher.
The breakout setup entry provides us with an awesome +3 Reward/Risk. A tighter stop loss order can even make it a lot better. A late entry at current prices provides 1.8-2.0 which is still a good ratio.
BioTech stocks are risky and volatile. This is not financial advice. DYODD
The breakout setup entry provides us with an awesome +3 Reward/Risk. A tighter stop loss order can even make it a lot better. A late entry at current prices provides 1.8-2.0 which is still a good ratio.
BioTech stocks are risky and volatile. This is not financial advice. DYODD